BURLINGTON, Mass.--(BUSINESS WIRE)--Fourth graph, last sentence should read: ... but immunomodulatory agents—specifically Celgene’s Revlimid—and PCI-32765 will also capture significant patient share and sales.
The corrected release reads:
PHARMACYCLICS/JANSSEN BIOTECH’S PCI-32765 HAS EARNED DECISION RESOURCES’ PROPRIETARY CLINICAL GOLD STANDARD STATUS FOR THE TREATMENT OF RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
PCI-32765 Will Displace the Current Proprietary Clinical Gold Standard for the Indication, R-EPOCH, According to Findings from Decision Resources
Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, based on clinical data and the opinions of interviewed thought leaders, Pharmacyclics/Janssen Biotech’s PCI-32765 has earned Decision Resources’ proprietary clinical gold standard status for the treatment of relapsed/refractory diffuse large B-cell lymphoma. Owing to its competitive advantages in efficacy, safety and tolerability and delivery, the Bruton’s tyrosine kinase inhibitor PCI-32765 (which will launch for the indication in 2017 in the United States and Europe) will displace Decision Resources’ current proprietary clinical gold standard for relapsed/refractory diffuse large B-cell lymphoma, R-EPOCH*.
“Clinical data and the opinions of interviewed thought leaders indicate that PCI-32765 displays promising efficacy in treating relapsed/refractory diffuse large B-cell lymphoma, a subpopulation of non-Hodgkin’s lymphoma—although a survival benefit over currently available therapies has yet to be demonstrated,” said Decision Resources Analyst Khurram Nawaz, M. Sc.
The DecisionBase 2012 report entitled Non-Hodgkin’s Lymphoma—Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Could an Emerging Therapy Obtain Commercial Success by Targeting This Population of High Unmet Need? finds that surveyed U.S. hematological oncologists would prescribe Pfizer’s inotuzumab ozogamicin to 40 percent of their patients with relapsed/refractory diffuse large B-cell lymphoma. Decision Resources forecasts that the uptake of inotuzumab ozogamicin, which will be limited by increasing competition from other therapies, will earn a 13 percent patient share in the U.S. relapsed/refractory diffuse large B-cell lymphoma drug market by 2020, with greater uptake in later lines of therapy.
Decision Resources’ analysis of the overall diffuse large B-cell lymphoma market (including first-line and relapsed/refractory settings) finds that it will increase from $1.5 billion in 2010 to $3.9 billion in 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan—representing an impressive 10.2 percent annual growth. Rituximab (Roche/Genentech/Chugai Seiyaku/Zenyaku Kogyo’s Rituxan/MabThera) will continue to dominate a more fragmented diffuse large B-cell lymphoma market over the forecast period, despite the entry of less-expensive biosimilar versions of rituximab. Monoclonal antibodies will remain the most commercially successful drug class through 2020, but immunomodulatory agents—specifically Celgene’s Revlimid—and PCI-32765 will also capture significant patient share and sales.
*R-EPOCH: rituximab plus etoposide (Bristol-Myers Squibb’s Etopophos/Vepesid, Pfizer/Nippon Kayaku’s Lastet, Baxter’s Celltop, generics), prednisone (Sanofi’s Cortancyl, Merck KGaA’s Decortin, generics), vincristine (Genus Pharmaceuticals/Nippon Kayaku’s Oncovin, generics), cyclophosphamide (Bristol-Myers Squibb’s Cytoxan, Pfizer’s Cyclophospham, generics) and doxorubicin (Pfizer’s Adriamycin/Adriblastine/Adriacin, generics).
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may
be trademarks or
registered trademarks of their respective holders.